Topics

FDA Approves Genentech’s Tecentriq Plus Chemotherapy for Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

10:31 EST 4 Dec 2019 | Speciality Pharma Journal

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane® [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or …

Original Article: FDA Approves Genentech’s Tecentriq Plus Chemotherapy for Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Genentech’s Tecentriq Plus Chemotherapy for Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...